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Simple Summary: Soft tissue sarcomas are a group of malignant tumors developing from connective
tissues in different parts of the human body. In the face of limited options for systemic therapy,
immunotherapeutic approaches are currently being explored. In this context, cancer testis antigens
(CTAs) are potential targets for cancer immunotherapy due to tumor-specific patterns of expression
and high immunogenicity. We, therefore, aimed to describe the expression of three CTAs, PRAME,
NY-ESO-1, and SSX2, and analyze their prognostic value in a large cohort of high-risk soft tissue
sarcomas with long-term follow-up. Our results show sarcoma subtype-specific patterns of CTA
expression and we demonstrate an association of CTAs with overall survival, especially for PRAME.
Our results provide support for future trials investigating CTA-directed immunotherapy in eligible
patients with various sarcoma subtypes and they may help establish CTAs as diagnostic tools in soft
tissue sarcoma.
Abstract: (1) Background: PRAME, NY-ESO-1, and SSX2 are cancer testis antigens (CTAs), which are
expressed in testicular germ cells with re-expression in numerous cancer types. Their ability to
elicit humoral and cellular immune responses have rendered them promising targets for cancer
immunotherapy, but they have never been studied in a large and well-characterised cohort of soft
tissue sarcomas (STS). (2) Methods: On a protein level, we examined PRAME, NY-ESO-1, and SSX2
expression in tumour tissues of 249 high-risk STS using immunohistochemistry. We correlated
expression levels with clinicopathological parameters including tumour-infiltrating lymphocyte (TIL)
Cancers 2020, 12, 3612; doi:10.3390/cancers12123612 www.mdpi.com/journal/cancers
Cancers 2020, 12, 3612 2 of 13
counts, grading, and long-term survival. (3) Results: Expression of PRAME, NY-ESO-1, and SSX2 was
observed in 25 (10%), 19 (8%), and 11 (4%) of 249 specimens with distinct patterns for histo-subtypes.
Expression of PRAME was associated with shorter patient survival (p = 0.005) and higher grade
(G2 vs. G3, p = 0.001), while NY-ESO-1 expression was correlated with more favourable survival
(p = 0.037) and lower grade (G2 vs. G3, p = 0.029). Both PRAME and NY-ESO-1 expression were more
frequent in STS with low TIL counts. In multivariate analysis, high PRAME and low SSX2 expression
levels as well as metastatic disease and non-radical resections were independent predictors of shorter
overall survival. (4) Conclusions: CTAs PRAME, NY-ESO-1, and SSX2 show distinct expression
patterns in different STS subtypes. These results demonstrate their prognostic relevance and may
guide future immunotherapeutic approaches in STS.
Keywords: soft tissue sarcoma; human; cancer/testis antigens; PRAME; NY-ESO-1; SSX2; biomarker;
tumour infiltrating lymphocytes; immunohistochemistry
1. Introduction
Soft tissue sarcomas (STS) are a heterogenous group of rare malignant tumours originating from
soft tissues that can occur in different parts of the human body. While treatment of localised disease is
based on radical resection, evidence from a limited number of trials supports the use of perioperative
systemic therapy in high-risk tumours [1,2]. Therapeutic options, however, are limited, and in a
recent trial, a histology-tailored regimen was inferior to standard chemotherapy with epirubicin and
ifosfamide [2]. Immunotherapy, which has been successfully introduced for several cancers, might be
an option to individualise therapy of sarcoma patients [3].
In normal tissues, expression of cancer-testis antigens (CTAs) is restricted to germ cells and
trophoblasts. They are aberrantly expressed in various types of cancer. Following their identification
in malignant melanoma, CTAs have been detected in carcinomas of various sites, such as lung, ovary,
urinary bladder, liver, and other organs [4]. Several CTAs, like MAGE, NY-ESO-1, and PRAME,
are expressed in different sarcoma subtypes, such as synovial sarcoma [5–11], myxoid/round cell
liposarcoma [6,11–16], and other soft tissues sarcomas. CTAs can be highly immunogenic and are
considered potential targets for immunotherapy of cancer [17].
Tumour-infiltrating lymphocytes (TILs) belong to the microenvironment of malignant tumours
and constitute an essential part of the human body’s dynamically changing reaction to the tumour.
While some TIL populations have been shown to promote tumour progression [18], others are
implicated in killing tumour cells or enhancing the tumour response to certain chemotherapeutics [19].
Although high TIL counts following neoadjuvant treatment of high-risk soft tissue sarcomas have been
associated with a more favourable prognosis [20], the role of TILs in chemo-naïve STS is less clearly
defined [21].
In the present study, we analyse the expression of CTAs NY-ESO-1, PRAME, and SSX2 in a large
and well-characterised cohort of high-risk soft-tissue sarcoma patients with long-term follow-up and
correlate our findings with the presence of TILs, clinical tumour characteristics, and survival data.
We show that PRAME, NY-ESO-1, and SSX2 display distinct expression patterns in different STS
subtypes. PRAME and NY-ESO-1 expression levels are correlated to patient survival and tumour
grade in opposing ways, while both CTAs are correlated with low TIL counts. In multivariate analysis,
high PRAME and low SSX2 expression levels as well as metastatic disease, non-radical resections,
and not receiving chemotherapy are shown to be independent predictors of shorter overall survival.
These results may guide future immunotherapeutic approaches in STS.
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2. Results
2.1. Patient Cohort
The study included 249 patients (female n = 125, male n = 124) with intermediate (n = 118) or
high-grade (n = 131) STS. The patients’ age at the time of diagnosis ranged from 18 to 79 years
(median age, 53 years). Parameters describing the tumours of included patients (histological
subtype, location, grading, size, and presence of metastatic disease) and their treatment (surgical
outcome, radiotherapy, and regional hyperthermia) are shown in Table 1. All patients received
anthracycline-based systemic therapy. Metastatic disease, if present, was judged as surgically
respectable at initial evaluation. Nearly all patients (n = 223, 89.6%) underwent surgical resection,
and about one in five patients received additional radiotherapy.
Table 1. Patient Characteristics. UPS: undifferentiated pleomorphic sarcoma; SFT: solitary fibrous
tumour; MPNST: malignant peripheral nerve sheath tumour.
n %
Total 249 100
Sex
Male 124 50
Female 125 50
Histological subtype
UPS 82 33
Leiomyosarcoma 50 20
Synovial sarcoma 28 11
Dedifferentiated Liposarcoma 47 19
Angiosarcoma 9 4
MPNST 13 5
Other 20 8
Location
Extremities 85 34
Retroperitoneal 54 22
Abdominal/visceral 42 17
Trunk 60 24
Other 8 3
Grading Intermediate (G2) 118 47
High (G3) 131 53
Size
<50 mm 20 8
50–79 mm 61 24
80–120 mm 64 26
>120 mm 76 31
Missing 28 11
Metastatic disease
M0 227 91
M1 22 9
Surgical margins R0/R1 202 81
R2 or no resection 47 19
Radiotherapy
Done 53 21
Not done 180 72
Unknown 16 2
Regional hyperthermia Done 195 78
Not done 54 22
2.2. Cancer-Testis Antigens Show Distinct Expression Patterns in Sarcoma Subtypes
Expression of PRAME, NY-ESO-1, and SSX2 was observed in 25 (10%), 19 (8%), and 11 (4%) of
249 specimens (248 specimens for SSX2), respectively. Examples of immunohistochemistry staining for
CTAs are shown in Figure 1, and detailed results of TMA analysis with respect to histologic subtypes
are shown in Table 2. Expression levels for all CTAs are shown in Table A1.
Cancers 2020, 12, 3612 4 of 13
Cancers 2020, 12, x FOR PEER REVIEW 4 of 14 
 
 
Figure 1. Representative micrographs of cores on a tissue microarray stained for (A) PRAME, (B) NY-
ESO-1, and (C) SSX2. Numbers represent semiquantitative scoring of immunostaining: 0, negative; 1, 
weak; 2, moderate and 3, strongly positive. Magnification 20×. 
Table 2. Cancer testis antigen expression and tumour-infiltrating lymphocytes (TILs) according to 
tumour entity: the table shows the number and percentage of patients with high antigen expression 
and high TIL infiltration. 
 Total PRAME NY-ESO-1 SSX2 TILs 
Histologic Subtype n n % n % n % n % 
UPS 82 a 6 7% 2 2% 3 4% 71 87% 
Leiomyosarcoma 50 3 6% 1 2% 0 0% 33 66% 
Synovial Sarcoma 28 3 11% 12 43% 7 25% 13 46% 
DDLPS 47 2 4% 3 6% 0 0% 39 83% 
Angiosarcoma 9 3 33% 1 11% 0 0% 8 89% 
MPNST 13 5 38% 0 0% 1 8% 11 85% 
Other 20 3 15% 0 0% 0 0% 18 90% 
Total 249 a 25 10% 19 8% 11 4% 193 78% 
UPS: undifferentiated pleomorphic sarcoma; DDLPS: dedifferentiated liposarcoma; SFT: solitary 
fibrous tumour; MPNST: malignant peripheral nerve sheath tumour. a 81 of 82 specimens were 
analysed for SSX2 expression; HPF: high power field. 
. Repr sen ative micrographs f cores on a tissue microarray stained for (A) PRAME,
(B) NY-ESO-1, and (C) SSX2. Number represent semiquantitative scoring of immu osta ning:
0, negative; 1, weak; 2, moderate and 3, strongly positive. Magnification 20×.
Table 2. Cancer testis antigen expression and tumour-infiltrating lymphocytes (TILs) according to
tumour entity: the table shows the number and percentage of patients with high antigen expression
and high TIL infiltration.
Total PRAME NY-ESO-1 SSX2 TILs
Histologic Subtype n n n % n n %
82 a 6 2% 3 4 71 87%
Leiomyosarcoma 50 3 6% 1 2% 0 0% 33 66%
Synovial Sarcoma 28 3 11% 12 43% 7 25% 13 46%
DDLPS 47 2 4% 3 6% 0 0% 39 83%
Angiosarcoma 9 3 33% 1 11% 0 0% 8 89%
MPNST 13 5 38 0 0% 1 8 11 85%
Other 20 3 15 0% 0 0 18 90%
Total 249 a 25 10 19 8% 11 4 193 78%
UPS: undifferentiated pleomorphic sarcoma; DDLPS: dedifferentiated liposarcoma; SFT: solitary fibrous tumour;
MPNST: malignant peripheral nerve sheath tu our. a 81 of 82 specimens were analysed for SSX2 expression;
HPF: high power field.
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2.3. Cancer-Testis Antigens PRAME and NY-ESO-1 Are Expressed More Frequently in Soft Tissue Sarcomas
with Low Counts of Tumour-Infiltrating Lymphocytes
Tumour-infiltrating lymphocytes (TILs) were found in 193 (78%) of 249 specimens. Examples of
H&E staining of TILs are depicted in Figure 2A,B, and detailed TIL counts for different histologic
subtypes are shown in Table 2. TIL counts were not statistically correlated to patient survival (Figure 2C).
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Figure 3. Counts of TILs for different expression levels of (A) PRAME, (B) NY-ESO-1, and (C) SSX2. 
Numbers represent semiquantitative scoring of immunostaining: 0, negative; 1, weak; 2, moderate; 
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Figure 2. (A) and (B): representative samples of UPS (A) with >4/HPF tumour-infiltrating lymphocytes
(TILs) (“positive”) and (B) without TILs (≤3/HPF, “negative”). Pictures are representative micrographs
of cores on an H&E stained tissue microarray. Black arrows pointed at TILs. Magnification 20×.
(C): Relationship between counts of tumour-infiltrating lymphocytes (TILs) and survival. No significant
correlation was found (R2 = 0.0002; p > 0.05).
PRAME expression tended to be more frequent in tumours with low numbers of TILs (9/56, 16.1%)
than in tumours with high TIL counts (16/193, 8.3%, p = 0.126, Figure 3). NY-ESO-1 expression was
three times more frequent in tumours with low TIL counts (9/56, 16.1%) than in tumours with high
numbers of TILs (10/193, 5.2%, p = 0.018, Figure 4). The low frequency of SSX2 expression did not
allow for a meaningful statistical analysis.
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2.5. PRAME Expression Is Prognostic of Shorter Survival while NY-ESO-1 Is Associated with a More
Favourable Prognosis
Median duration of follow-up was 40 months for all patients, 96 months for 110 patients still alive,
and 31 months for 139 patients who had died. An analysis of overall survival using the Kaplan–Meier
method is shown in Figure 4. Patients with PRAME-positive tumours had statistically significant
shorter median survival (23.0 (13.5–32.5) months vs. 69.0 (44.4–93.6) months, p = 0.005), while high
NY-ESO-1 expression was associated with improved survival (>120 months vs. 58.0 (39.4–76.6) months,
p = 0.037). The expression of SSX2 had no significant impact on overall survival. The results of
univariate survival analysis for CTAs and clinical parameters are shown in Table A2.
2.6. Expression of CTAs PRAME und SSX2 As Well As Radical Resections, Chemotherapy, and Metastatic
Disease Influenced Overall Surivival in Multivariate Analysis
To control for confounding factors, a Cox proportional hazards model for overall survival was
calculated including the expression of CTAs, treatment variables, and tumour characteristics in a
stepwise procedure (Table 3). High PRAME expression levels (HR 2.675 (1.548–4.622), p < 0.001) and
low expression of SSX2 (HR 3.054 (1.060–8.796), p = 0.039) were independent predictors of shorter
overall survival. Furthermore, radical resection and the absence of metastatic disease were associated
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with favourable survival (Table 3). The expression of NY-ESO-1, histological subtype, the use of
radiotherapy, or regional hyperthermia and TIL counts did not contribute significantly to the risk of
death and, therefore, did not enter the final model.
Table 3. Multivariate analysis of overall survival: a Cox proportional hazards model for overall survival
was calculated including cancer testis antigens (CTAs) and clinical parameters in a stepwise procedure.
HR, hazard ratio.
HR (95% CI) p
Metastatic disease
M0 1
<0.001M1 3.182 (1.875–5.401)
Surgical margins R0/R1 1 <0.001R2 or no resection 2.531 (1.682–3.809)
PRAME
Low 1
<0.001High 2.675 (1.548–4.622)
SSX2 High 1 0.039
3. Discussion
In this study, we analysed the expression of CTAs PRAME, NY-ESO-1, and SSX2 as well as the
presence of tumour-infiltrating lymphocytes (TILs) in a well-characterised cohort of high-grade soft
tissue sarcoma patients. Although several CTAs have been studied extensively in the past, little is
known about PRAME as well as SSX2 on the in-situ protein expression level. Both antigens were
chosen because of the lack of data pertaining their presence in sarcoma. NY-ESO-1 was chosen to serve
as a reference because it is among the well-studied CT antigens.
We found the expression of PRAME and the presence of a high number of TILs to be associated
with shorter survival, while NY-ESO-1 expression was more frequent in patients with a more favourable
prognosis. Furthermore, the expression of PRAME was associated with higher grade and a lower
number of TILs while NY-ESO-1 expression was correlated with lower grade and low TILs. Finally,
high PRAME expression was confirmed as a prognostic factor for overall survival in a Cox proportional
hazards model that included clinical parameters like metastatic disease and surgical margins. To our
knowledge, the present study of 249 patient cases is the largest study of CTAs in soft tissue sarcoma
demonstrating a prognostic significance of these markers.
Significant PRAME overexpression has been described in uterine carcinosarcoma, synovial
sarcoma, and multifocal leiomyosarcoma, while other sarcoma subtypes appear to express PRAME
less frequently [22]. In the present study, we found PRAME expression in undifferentiated
pleomorphic sarcoma (UPS), malignant peripheral nerve sheath tumour (MPNST), synovial sarcoma,
leiomyosarcoma (LMS), angiosarcoma, dedifferentiated liposarcoma (DDLPS), uterine carcinosarcoma,
and rhabdomyosarcoma, making PRAME a potential target for immunotherapy in these histological
subtypes. Moreover, in our mixed cohort of intermediate and high-grade sarcomas, PRAME expression
was prognostic for unfavourable survival, which was not the case in the studies of liposarcoma,
leiomyosarcoma, and synovial sarcoma subgroups by others [9,22]. Our results, therefore, might help
establish PRAME both as a prognostic marker that can be used in nomograms and as a valuable
target antigen in soft tissue sarcoma. The fact that we were able to demonstrate PRAME expression
in only 3 of 28 synovial sarcomas compared to 100% overexpression in a gene expression study by
Roszik et al. [22] might be due to different methods, detection of PRAME on protein level, and scoring
evaluation. The potential of PRAME as a target for immunotherapy may, therefore, be more important
than suggested by our results. Future studies should also assess the prognostic value of CTAs in
specific histological subtypes.
Currently, PRAME is a target antigen in a clinical phase I trial evaluating multi-tumour-associated
antigen-specific cytotoxic T lymphocytes in rhabdomyosarcoma (NCT02239861, TACTASOM).
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Given that PRAME expression was negatively correlated with lymphocyte infiltration in our study
and that PRAME has been described to downregulate antigen-presentation [22], effective strategies for
T-cell recruitment and activation will be needed. These may include a boost of MHC class I expression
using, e.g., demethylating drugs and other approaches [23], combinatorial therapy with NK cells [24],
or checkpoint inhibitors [25].
Our multivariate regression analysis suggests that the prognostic value of PRAME expression
is robust, even in relation to established clinical parameters such as surgical margins or metastatic
disease. Nonetheless, while most biopsies were taken before the initiation of neoadjuvant treatment,
some patients had received radiotherapy, chemotherapy, and/or hyperthermia before histopathological
sampling for this study. Radiotherapy potentially induces gene mutations and alters the expression of
CTAs [26], which may have influenced our results.
NY-ESO-1 has been studied extensively in various cancers. We found it to be expressed in almost
half of synovial sarcomas and in some cases of UPS, LMS, DDLPS, and angiosarcoma. This essentially
confirms the results of previous studies, although expression in synovial sarcoma has been demonstrated
to be as high as 76% to 80% [10,27,28]. In our cohort of soft tissue sarcoma patients, NY-ESO-1 expression
was associated with lower grade, and it was prognostic of more favourable survival, as has been shown
in a series of high-grade soft tissues sarcoma by Kakimoto et al. [27]. Interestingly, in non-small-cell lung
cancer, high NY-ESO-1 expression was associated with poor prognosis [29], while in epithelial ovarian
cancer [30] and breast cancer [31] no relationship with survival has been found. These discrepancies may
be caused by the variability of specific interactions between different NY-ESO-1-expressing tumours
and their microenvironment, including altered expression of tumour antigens, epitope spreading,
and the induction of immunosuppressive cells [32]. Furthermore, NY-ESO-1 is highly immunogenic,
and expression might stimulate a T-cell response in some tumours.
Widespread expression across various cancer types has made NY-ESO-1 an attractive target
for different immunotherapeutic strategies such as adoptive cell transfer [33,34], cancer vaccines
(NCT01883518), and immune checkpoint inhibition [35]. While its strong immunogenic nature implies
that therapies directed against NY-ESO-1 may also boost the natural immune response, its restricted
expression in normal tissue presumably limits off-target toxicities [32].
Interestingly, in our study, NY-ESO-1 and PRAME were expressed more often in tumours with low
TILs. The suppression of CD3+ T-lymphocytes has been described in malignant-melanoma-expressing
NY-ESO-1, although its mechanism remains unclear [36]. In a previous analysis of our cohort,
the expression of PD-L1 on STS was associated with an infiltration by PD-1-positive TILs, high tumour
grading, and short survival [37]. These results point to an actual PD-L1 interaction with PD-1-positive
TILs in STS and support checkpoint inhibitor therapy in eligible patients. While lymphocyte infiltration
is a prerequisite for this approach, it appears that non-T-cell inflamed tumours, which are resistant to
PD-1/PD-L1 inhibitors and which were more frequent among NY-ESO-1 and PRAME-positive STS in
the present study, can still be treated with adoptive T-cell based immunotherapy [38]. Targeting CTAs
may, therefore, provide a therapeutic option in patients not eligible for checkpoint inhibitor therapy.
Although high SSX2 expression was prognostic of favourable survival in multivariate analysis,
the low overall frequency of SSX2 expression in the present study did not allow for a meaningful
statistical analysis of this CTA in relation to TILs or grading. The SS18-SSX2 fusion, however, was a
frequent finding in synovial sarcomas in the analysis of the Cancer Genome Atlas [39]. SSX2 may,
therefore, be a target in synovial sarcomas, which were SSX2-positive in 25% in our study and which
are treated with SSX2-directed cytotoxic T-lymphocytes in the TACTASOM trial (NCT02239861).
Our study has several limitations. First, no conclusions can be drawn about the prognostic
value of CTAs in specific histological subtypes due to the limited number of patient cases. Second,
in this specific cohort based on the EORTC-STBSG 62961 trial protocol [40], the majority (78%) of
patients received regional hyperthermia, which limits the external validity of our results. Finally,
the generalisability of our conclusions is limited by the fact that in 25% of patients, biopsies used in
this study had been taken after the initiation of neoadjuvant treatment. Although we have found no
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indication in our data that systemic therapy influenced CTA expression, results may not be transferable
to patients not having undergone neoadjuvant treatment.
4. Materials and Methods
4.1. Patients
A total of 249 cases of high-risk STS were retrieved from the archives of the Institute of Pathology
at Ludwig-Maximilians-Universität (LMU) Munich, Germany. Patients were diagnosed and treated
between 1989 and 2012 at the sarcoma centre of LMU University Hospital. Data on clinical parameters
were extracted from the original pathology reports and the database of the previously published
EORTC-STBSG 62961 trial (NCT00003052) [40]. This included sex; age; primary site; histological
subtype; grading; size; presence of metastatic disease; surgical outcome; and whether radiotherapy,
chemotherapy, and/or regional hyperthermia had been performed. Patients were followed in outpatient
clinics or by contacting their general practitioner, and clinical data were updated until December 2019.
The study has been approved by the institutional review board at LMU Munich (No. 20-127).
4.2. Histopathology and Tissue Microarray Construction Immunohistochemistry
Biopsies were taken deep from dedifferentiated areas of the tumour before the initiation of
neoadjuvant treatment if possible; in 61 patients (25%), only biopsies taken after the initiation
of neoadjuvant treatment were available for this analysis. In addition to the original pathology
reports, microscopic findings (tumour type according to current WHO classification and degree of
differentiation) were reassessed by two authors (E.K. and T.K. (Thomas Knösel)). For tissue microarray
(TMA) assembly, representative tumour areas were marked on H&E stained slides of formalin-fixed,
paraffin-embedded tumour samples from all patients according to standard procedures [41] and two
0.6 mm punch biopsies were taken of each sample. Samples from tonsils were added as controls.
4.3. Immunohistochemistry of Cancer Testis Antigens
Expression of CTAs NY-ESO-1, PRAME, and SSX2 was defined as the primary outcome of
this study. Immunohistochemical staining was done on 5 µm TMA sections according to standard
procedures. Antibodies against NY-ESO-1, PRAME, and SSX2 were obtained and used for the analysis
as detailed in Table 4. All assays were performed on a Leica Bond-3 automated stainer platform
(Leica, Buffalo Groves, IL, USA). Before application of the primary, heat-based antigen retrieval was
performed employing a high pH buffer (ER2, Leica). A polymeric secondary kit (Refine, Leica) was
used to detect the primary. Immunostaining was evaluated and scored semi-quantitatively by two
investigators (M.A. and T.K. (Thomas Knösel)) on a four-tier scale: 0, negative; 1, weak; 2, moderate
and 3, strongly positive, that was reduced to a 2-tier system (0—low, versus 1/2/3—high for PRAME
and SSX2, 0/1/2—low, versus 3, high for NY-ESO-1) for statistical analysis. Five fields were scored for
each sample and from duplicate samples; the higher score was used for statistical analysis. In case of
discrepancy between the two investigators (n = 12), samples were jointly reviewed and a consensus
was reached. Researchers scoring the TMAs were blinded to the clinical data.
Table 4. Antibodies used for immunohistochemistry staining. ER2: epitope retrieval solution 2.
Antigen Product No. Supplier Clone Dilution Pre-Treatment
NY-ESO-1 SC-53869 Santa Cruz E978 1:100 ER2
PRAME ab219650 Abcam EPR20330 1:1000 ER2
SSX2 AMAb91141 Atlas Antibodies CL3202 1:3000 ER2
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4.4. Tumour-Infiltrating Lymphocytes
Tumour-infiltrating lymphocyte (TIL) counts were defined as a secondary outcome parameter.
TILs comprised all mononuclear cells and were counted per high power field (HPF, 400×magnification)
in H&E stained TMA slides. Samples with counts of at least four lymphocytes per HPF were considered
positive. From duplicate samples, the higher score was used for statistical analysis.
4.5. Statistical Analysis
Categorical variables were tested for independence using the Chi square test.
Survival was calculated from the date when sarcoma was first diagnosed. Overall survival
(patients’ death without regarding the cause of death) was used as the endpoint for estimating
prognosis. Survival curves were created using the Kaplan–Meier method, and the log-rank test was
used to assess differences in survival.
Significant and independent predictors of overall survival were identified by Cox proportional
hazard analysis. The forward stepwise procedure was set to a threshold of 0.05. All statistical analyses
were performed using SPSS 26.0 (IBM, Chicago, IL, USA) software (Figure 3: GraphPad Prism version
8.4.2, GraphPad Software, San Diego, CA, USA).
Statistical significance was defined as a p value < 0.05 for all analyses.
5. Conclusions
CTAs PRAME, NY-ESO-1, and SSX2 show distinct expression patterns in different STS subtypes.
PRAME and SSX2 are prognostic for overall survival and may be used in future nomograms of survival
in STS. PRAME and NY-ESO-1 expression levels are correlated to patient survival and tumour grading
in opposing ways, while both CTAs are more frequent in tumours with low TIL counts. These results
may guide future immunotherapeutic approaches in STS.
Author Contributions: Conceptualization, M.A., A.A.J., and T.K. (Thomas Knösel); Data curation, R.D.I.,
E.K., and G.S.-F.; Formal analysis, M.A., A.A.-H., and T.K. (Thomas Knösel); Investigation, M.A.,
A.A.-H., R.D.I., G.S.-F., A.A.J., and T.K. (Thomas Knösel); Methodology, M.A., A.A.-H., E.K., A.A.J.,
and T.K. (Thomas Knösel); Project administration, M.A., E.K., and T.K. (Thomas Knösel); Resources, L.H.L.,
R.D.I., M.K.A., T.K. (Thomas Kirchner), and T.K. (Thomas Knösel); Software, A.A.-H. and G.S.-F.; Supervision,
L.H.L., H.-R.D., M.K.A., and T.K. (Thomas Kirchner); Visualization, M.A. and A.A.-H.; Writing—Original draft,
M.A.; Writing—Review and Editing, L.H.L., H.-R.D., M.K.A., A.A.J., and T.K. (Thomas Knösel). All authors have
read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Acknowledgments: The authors thank Sultan Abdel-Rahman for clinical data consolidation.
Conflicts of Interest: The authors declare no conflict of interest.
Appendix A
Table A1. Frequency of levels of expression for different Cancer Testis Antigens: 0, negative; 1, weak; 2,
moderate and 3, strongly positive.
Expression PRAME NY-ESO-1 SSX2
n % n % n %
0 224 90.0 214 85.9 237 95.6
1 6 2.4 8 3.2 2 0.8
2 8 3.2 8 3.2 4 1.6
3 11 4.4 19 7.6 5 2.0
Total 249 100.0 249 100.0 248 100.0
Missing 1
Cancers 2020, 12, 3612 11 of 13
Table A2. Univariate analysis of risk factors for overall survival by Cox regression: HR, hazard ratio.
HR (95% CI) p
Metastatic disease
M0 1
<0.001M1 3.173 (1.889–5.330)
Surgical margins R0/R1 1 <0.001R2 or no resection 1.618 (1.328–1.972)
PRAME
Low 1
0.117High 1.181 (0.959–1.453)
SSX2
High 1
0.229Low 1.841 (0.681–4.982)
NY-ESO-1
High 1
0.096Low 1.600 (0.921–2.782)
TILs count
Low 1
0.635High 1.207 (0.804–1.811)
Histological subgroup 1.061 (1.007–1.119) 0.028
Radiotherapy Not done 1 0.455Done 1.166 (0.779–1.743)
Regional hyperthermia Not done 1 0.085Done 1.446 (0.950–2.200)
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